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Purpose: Progression of chronic myeloid leukemia (CML) is frequently associated with
increased angiogenesis at the bone marrow mediated by exosomes. The capability of gold
nanoparticles (AuNPs) functionalized with antiangiogenic peptides to hinder the formation of
new blood vessels has been demonstrated in a chorioallantoic membrane (CAM) model.
Methods: Exosomes of K562 CML cell line were isolated and their angiogenic effect
assessed in a CAM model. AuNPs functionalized with antiangiogenic peptides were used
to block the angiogenic effect of CML-derived exosomes, assessed by evaluation of expres-
sion levels of key modulators involved in angiogenic pathways - VEGFA, VEGFR1 (also
known as FLT1) and IL8.
Results: Exosomes isolated from K562 cells promoted the doubling of newly formed vessels
associated with the increase of VEGFR1 expression. This is a concentration and time-
dependent effect. The AuNPs functionalized with antiangiogenic peptides were capable to
block the angiogenic effect by modulating VEGFR1 associated pathway.
Conclusion: Exosomes derived from blast cells are capable to trigger (neo)-angiogenesis, a
key factor for the progression and spreading of cancer, in particular in CML. AuNPs functio-
nalized with specific antiangiogenic peptides are capable to block the effect of the exosomes
produced by malignant cells via modulation of the intrinsic VEGFR pathway. Together, these
data highlight the potential of nanomedicine-based strategies against cancer proliferation.
Keywords: chronic myeloid leukemia, exosomes, chorioallantoic membrane, gold
nanoparticles, angiogenesis
Introduction
Chronic myeloid leukemia (CML), characterized by the uncontrolled proliferation
of myeloid cells, has an incidence of 1–2 cases per 100,000 adults and accounts for
circa 15% of newly diagnosed leukemia cases in adults.1 CML is caused by the
fusion of the Abelson murine leukemia (ABL1) gene on chromosome 9 with the
breakpoint cluster region (BCR) gene on chromosome 22, forming an aberrant
chromosome designated by Philadelphia chromosome.2 This translocation results
in a BCR-ABL1 fusion gene encoding a tyrosine kinase with permanent-elevated
activity, resulting in enhanced cell proliferation.2 CML patients initial treatment
rely on tyrosine kinase inhibitors that block the aberrant fusion protein.1 This
aberrant proliferation, in turn, triggers a range of cell and molecular events in the
bone marrow, which correlate with disease progression and prognosis.3 In the bone
marrow tumor microenvironment, autocrine and paracrine communication between
malignant cells and bone marrow cells are crucial for modulation and evolution of
the niche.3,4 For example, it has been previously reported the direct correlation
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between blast transformation and the caliber and density of
microvessels in the bone marrow.3
Exosomes are small vesicles with 30–100 nm diameter
formed in the endosomal pathway, usually composed by a
lipid bilayer containing membrane proteins capable to
encapsulate nucleic acids, such as mRNA and miRNAs,
proteins and several other molecules involved in cellular
communication (eg, cytokines and growth factors).5,6 After
release to the extracellular milieu, exosomes are pivotal for
the communication between adjacent cells and for endo-
crine communication upon entering circulation (blood and
lymph).7,8 It has also been demonstrated the capability of
exosomes to trigger (neo)-angiogenesis, a crucial step for
the progression and evolution of cancer.9–11 Perhaps the
most striking feature of exosomes is their ability to alter
the phenotype of secondary cells once they internalize.12
Regarding exosomes secreted by CML cells, several
reports have demonstrated their capability to induce the for-
mation of new vessels, suggesting their role in neo-angiogen-
esis in the bone marrow of CML patients.11,13–18 Despite the
mechanisms involved in this event not being fully under-
stood, several key molecules involved in angiogenesis have
been identified within exosomes derived from CML, such as
the pro-angiogenic miRNAs, miR-92, and miR126.13,18
Moreover, K562 derived exosomes were found to induce
angiotube formation in human umbilical endothelial cells
(HUVEC) in a SRC-dependent way.14 Also, exosomes
secreted by LAMA84 CML cells induced the expression of
interleukin-8 (IL-8) in HUVEC.11 More recently, Conrado et
al, found that exosomes collected from blood from CML
patients contain amphiregulin, which activates epidermal
growth factor receptor (EGFR) in stromal cells located in
the bone marrow.16 Stromal cells activated through EGFR
secret IL-8, which then stimulates the proliferation of CML
cells.16
Nanomedicine has been putting forward several innova-
tive therapeutic tools to manage hematological
malignancies.4,19 Particularly, the versatility of nanoparticles
makes them suitable for use in a large range of applications,
from imaging and diagnosis to therapy.4,19,20 It has been
proposed that the enhanced permeability and retention effect
at the tumor location, resulting in altered endothelial, potenti-
ates nanomedicines accumulation at the site, with concomi-
tant improvement to drug delivery and efficacy.4,19,20
We have previously shown that gold nanoparticles
(AuNPs) designed to interact with neuropilin-1 receptor
(NRP-1) were effective at modulating angiogenesis in
vitro and in vivo without toxicity.21–24 In fact, by using
a chorioallantoic membrane (CAM) model, it was
shown that an 86% decrease of newly formed arterioles
was possible upon delivery of antiangiogenic AuNPs,
whose effect could be further potentiated by the direct
laser irradiation.21,22 The exact role of membrane gly-
coprotein NRP-1 in angiogenesis is still not completely
understood but it is accepted that NRP-1 enhances the
binding of the vascular endothelial growth factor
(VEGF) to VEGF receptors 1 and 2 (VEGFR-1 and
VEGFR-2).25
Here, the potential of antiangiogenic AuNPs to circum-
vent the effect of CML-derived exosomes in triggering the
development of new vessels was evaluated (Figure 1).
Materials and methods
Cell cultures and cell cultures maintenance
The CML cell line K562 (ATCC Cat# CCL-243, RRID:
CVCL_0004, Manassas, VA, USA), with the BCR-ABL1
e14a2 fusion transcript, and the human primary dermal nor-
mal fibroblasts, neonatal (ATCC Cat# PCS-201–010, Lot:
61728499) were cultured on Dulbecco’s modified eagle
medium (DMEM, ThermoFisher Scientific, Waltham,
Massachusetts, USA) supplemented with 10% (v/v) heat-
inactivated fetal bovine serum (FBS, ThermoFisher
Scientific) and a mixture of 100 U/mL Penicillin and 100
µg/mL Streptomycin (ThermoFisher Scientific). Cultures
were maintained at 37°C, 5% (v/v) CO2, and 99% (v/v)
relative humidity.
Figure 1 Antiangiogenic gold nanoparticles block the chronic myeloid leukemia
(K562) derived exosomes induced angiogenesis.
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Exosome isolation and characterization
Cell cultures for exosome isolation
When Fibroblast cultures reached 80% confluency, cells
were detached using Tryple Express (ThermoFisher
Scientific), centrifuged at 300×g for 5 mins, washed two
times with phosphate buffer saline (PBS), and 1×105 cells
were seeded in T-flasks with 25 cm2 area containing 5 mL
DMEM supplemented with 10% (v/v) heat-inactivated
exosome depleted FBS (ThermoFisher Scientific). After
24 hrs incubation, to ensure that cells adhere to the flask
surface, the medium was replaced by 5 mL identical fresh
medium and cells were incubated for 72 hrs. The super-
natant was then collected, centrifuged at 3000×g to
remove cell debris and stored at −80°C until use.
When K562 cultures reached a density of 1×106 cells/mL,
cells were pelleted by a centrifugation of 300×g, 5 mins and
washed three times with PBS. Cells were then seeded in a
density of 2×105 cells/mL in T-flasks with 25 cm2 area con-
taining 5 mL DMEM supplemented with 10% (v/v) heat-
inactivated exosome depleted FBS. After 72 hrs incubation,
the supernatant was collected, centrifuged at 3000×g to
remove cells and cell debris and stored at −80°C until use.
Exosome isolation
For exosome isolation, supernatants were slowly thawed and
filtered by a syringe filter with 0.2 µm diameter. The filtered
solution was concentrated in a Centrifugal device with 3KD
pore (PALL, New York, USA) and resultant suspension
(concentrated solution) was mixed with Total exosome iso-
lation reagent (from cell culture media, ThermoFisher
Scientific) according to manufacturer’s instructions. After
15 hrs incubation at 4°C, the mixture was centrifuged at
10,000×g, 1 hr, 4°C, the supernatant was completely
removed, and pelleted exosomes were solubilized in PBS.
Exosomes were stored at –80°C until needed.
The successful exosome isolation was confirmed by the
presence of CD-81 in samples and by dynamic light scat-
tering (DLS). The total protein concentration in the exo-
some solutions was measured using the Pierce 660 nm
Protein Assay reagent (ThermoFisher Scientific).
Western-blot for CD-81 detection
For Western-blot analysis, 30 µg protein of concentrated
solution of K562- and fibroblasts-derived exosomes suspen-
sions was mixed with loading buffer (70 mM Tris-HCl, pH
6.8, 10% (v/v) Glycerol, 1% (w/v) sodium dodecyl sulfide
(SDS), 1% (w/v) Dithiothreitol and 0.005% (w/v) bromo-
phenol blue) and incubated for 2 hrs at room temperature.
Afterward, proteins were separated in an SDS-polyacryla-
mide gel electrophoresis (SDS-PAGE) using a 10% (w/v)
polyacrylamide gel with 37.5:1 ratio of acrylamide: bisa-
crylamide and then transferred to a 0.45 µm PVDF mem-
brane (GE Healthcare, Chicago, Illinois, USA). Resultant
membrane was stained with Ponceau S solution (Biotium,
Fremont, California, USA) according to manufacturer´s
instructions and incubated with 5% (w/v) non-fat dry milk
in TBST (Tris-buffer saline with 0.1% (v/v) Tween-20) for
2 hrs at room temperature and for 2 hrs at 4°C. Blots were
then incubated over-night at 4°C with CD-81 antibody
(1D6, Novus biologicals Cat# NB100-65,805, RRID:
AB_962702, Littleton, Colorado, USA) in a final concen-
tration of 1.5 µg/mL in 5% (w/v) non-fat dry milk in TBST,
washed three times with TBST and incubated for 1 hr with
secondary antibody anti-mouse IgG, HRP-linked antibody
(Cell Signaling Technology Cat#7076, RRID:AB_330924,
Danvers, Massachusetts, USA). After washing three times
with TBST, blots were treated with Westernbright ECL
HRP substrate (Advansta, San Jose, California, USA) and
visualized by exposing the blots in a Hyperfilm ECL (GE
Healthcare).
Dynamic light scattering
The DLS analysis was made to examine the population
size of the K562 exosomes sample. This analysis was
performed in an SZ-100-sizer from Horiba Scientific
(Irvine, California, USA) using samples with a 50 µg/mL
protein concentration and the following parameters, ana-
lysis of organic sample particles in water, 25°C, plastic
cells, detector at 90º, general load, cut noise of 5 s, ND
filter 100% and standard polydispersion. Three measures
were performed in each reading. Z-value results represent
the average and standard deviation of three independent
readings.
AuNPs synthesis and characterization
AuNPs were synthesized and conjugated to oligo ethylene
glycol (OEG) and peptides as previously reported.21–24,26
Briefly, the synthesis of spherical AuNPs (13±2 nm) was
performed according to previously described procedures.27
A hot aqueous solution of trisodium salt (5 mL, 2% (w/v))
was added under stirring to a boiling aqueous solution.
Formation of AuNPs was indicated by the formation of a
deep red color. After stirring for further 15 mins and cooling
to room temperature, AuNPs were filtered using a 0.2 µm
syringe filter and stored at 4°C until use. These AuNPs were
then caped with (1-mercaptoundec-11-yl) hexathylene
Dovepress Roma-Rodrigues et al
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glycol (OEG, MW =526.7 g/mol) by adding 200 µL OEG
to 10 mL of AuNPs 5 nM. After stirring for 2 hrs and an
over-night incubation at 4°C, excess unbounded OEG was
removed by three centrifugations at 14,000×g for 15 mins
and AuNPs@OEG re-dispersion in borate buffer (10 mL,
0.01 M, pH9). AuNPs@OEG were then functionalized with
antiangiogenic peptide (KATWLPPR), as previously
described.23,27 Succinctly, 100 µL peptide 1 mg/mL in
0.01 M sodium borate, pH9 was added to 5 mL
AuNPs@OEG 1.5 nM in 0.01 M sodium borate buffer,
pH9. After addition of 50 µL 1-(3-(dimethylamino)pro-
pyl)-3-ethyl-carbodiimide methiodide 0.2 M in water, and
100 µL sulfo-N-hydroxysulfosuccinimide 0.2 M in water,
the mixture was shaken for 24 hrs at RT, purified by three
centrifugations at 16,400 rpm for 15 mins, re-dispersed in
water and lyophilized. Confirmation of the functionalization
of the antiangiogenic-AuNPs (AuNPs coated with OEG and
functionalized with antiangiogenic peptide) was performed
using UV-Vis and DLS as described elsewhere.21,22
Ex-ovo CAM assays
The CAM assays were performed in agreement with the
Directive 2010/63/EU of the European Parliament and of
the council of 22 September 2010 on the protection of
animals used for scientific purposes and, by using this
alternative animal model, obeying to the “3Rs policy” for
animal experiments. Fertilized eggs were acquired from
Pinto Valouro (Bombarral, Portugal).
The CAM experiments proceeded according to a pre-
viously described protocol with minor modifications.21,28
After 72 hrs incubation at 37°C, 90% (v/v) relative humid-
ity, fertilized eggs were gently opened into white weighing
boats (L89xP89xA25mm) covered with an identical punc-
tured weighing boat, allowing the yolk sack blood vessels
to be faced upwards. Eggs were allowed to stabilize for
another 24 hrs at 37°C, 90% (v/v) relative humidity, and
four silicone O-rings (inside diameter 8 mm) were placed
equidistantly above the blood vessels of the same embryo,
unless otherwise stated. If the embryo showed evidence of
severe stress (eg, under-development), they were not con-
sidered for analysis. As control, 40 µL of PBS was added
to the respective O-ring. Images of the O-ring interior
were acquired at specific time-points as indicated using a
digital USB Microscope Camera (Opti-Tekscope OT-V1).
Firstly, the internal area of the O-ring was selected and
image analysis performed using FIJI software as described
before.21 The percentage of newly formed vessels, which
were considered exclusively as vessels with lower caliber
sprouting from primary or secondary vessels, was calcu-
lated relatively to the 0 hrs time point and to the number of
newly formed arterioles in the negative control.
Specific details of each set of experiments as indicated:
Effect of K562 derived exosomes on angiogenesis
To assess the effect of CML-derived exosomes in angio-
genesis, CAMs were challenged with different amounts of
K562 exosomes corresponding to 5 µg/mL or 50 µg/mL
total protein inside different O-rings of the same chicken
embryo. Eggs (total 11) were then incubated at 37°C, 90%
(v/v) relative humidity. Images of the O-ring interior were
acquired at 0, 24, 48, and 72 hrs.
Effect of antiangiogenic-AuNPs
To each O-ring placed on the yolk sac membrane of the
same chicken embryo, it was inserted 40 µL of 1) PBS; 2)
50 µg/mL of Fibroblasts derived exosomes suspension, 3)
50 µg/mL of K562 derived exosomes suspension, or 4) a
mixture of 50 µg/mL of K562 derived exosomes suspen-
sion with 16.4 nM antiangiogenic-AuNPs (0.01 pmol/µL
for final peptide concentration).21 Embryos (total 8) were
incubated at 37°C, 99% (v/v) relative humidity and images
of the O-ring interior acquired at 0, 24, and 48 hrs.
mRNA expression analysis
Gene expression analysis was performed as previously
described.22 To ensure that no cross-effect between chal-
lenges was observed, every O-ring of each embryo was
infused with the same stimulus. After 12 and 24 hrs incuba-
tion at 37°C, 99% (v/v) relative humidity, CAMs were
excised and transferred to a microfuge tube. Total RNA
was extracted using NZYol reagent (NZYtech, Lisbon,
PT), according to the manufacturer's instructions. cDNA
synthesis and amplification of Glyceraldehyde 3-phosphate
dehydrogenase (GAPDH coding for GAPDH), interleukin-8
(IL8 coding for IL-8), vascular endothelial growth factor A
(VEGFA coding for VEGFA) , and vascular endothelial
growth factor receptor 1 (FLT1/VEGFR1 coding for
VEGFR-1) were performed as previously described, using
NZY qPCR green master mix (NZYtech).22 IL8, VEGFA,
and VEGFR1 expression were analyzed using the Ct
method (2 −ΔΔCt), with GAPDH as housekeeping gene and
samples treated with PBS as control.29 It was considered as
significantly altered expression when 2 −ΔΔCt was higher
than 2 or lower than 0.5.
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Statistical analysis
Presented results are the mean ± standard error of at least
three independent experiments. Statistically, difference
was considered for p-value <0.05 calculated using
Student t-test, or other unpaired t-test specified in the
results section. Statistical analysis was performed using
GraphPad prism vs 7.00 (GraphPad Software, Inc, San
Diego, CA, USA).
Results
Exosomes isolation and characterization
CML-derived exosomes were isolated from K562 cells in
exponential growth. Confirmation of exosome presence in
vesicle containing supernatant was achieved via Western-
blot for identification of CD-81 protein, a distinctive mar-
ker of exosomes (Figure S1A and B). DLS analysis
showed that the particle dispersion of the solution revealed
a gaussian curve with a peak below 100 nm (Figure S1C),
with a Z-value of 70.3±2.6 nm, confirming isolation of
exosomes. Together, these data indicate successful isola-
tion of exosomes from K562 cultured cells and the total
protein concentration of exosomes solutions was deter-
mined (further used as a surrogate indicator of exosome
concentration).12,14
Effect of K562 exosomes on angiogenesis
An ex-ovo CAM assay was used to assess the effect of
K562 exosomes on angiogenesis. O-rings were placed on
different locations of the CAM (Figure 2A) and filled with
K562 exosomes (0, 5, or 50 µg/mL). Following incuba-
tion, the percentage of newly formed arterioles was calcu-
lated by normalizing the number of tertiary vessels in the
K562 exosomes treated areas (Figure 2C and D) to the
number of tertiary vessels of the areas treated with control,
ie, PBS (Figure 2B).
Results showed that exposing the yolk sack membrane
to low amounts of exosomes (5 µg/mL) did not induce a
significant increase of newly formed vessels after 24 hrs
incubation (Figure 2B, C, and E). However, an increased
exposure to exosome concentration (50 µg/mL) doubled
the number of newly formed arterioles for the same period
of time (Figure 2B, D, and E). At 72 hrs, the effect of
exosomes in forming new vessels decreased to the basal
level (Figure 2E). These results agree with those obtained
by Mineo et al, where it was observed that treatment of
HUVEC with 5 µg/mL K562 derived exosomes resulted
only in morphological alteration of the cells, while treat-
ment with a higher concentration (10 µg/mL) caused the
development of a tube network.14
K562 exosomes






































Figure 2 Image of the chicken embryo aspect (A) and of the interior of each O-ring placed on the chorioallantoic membrane (CAM). Images were acquired after 24 hrs
incubation with 0 µg/mL (B), 5 µg/mL (C) or, 50 µg/mL (D) of K562 derived exosomes. Whiskers plots of the percentage of newly formed vessels after exposure to 5 µg/mL
(gray bars) or 50 µg/mL (black and white bars) of K562 exosomes (E). Bars represent the maximum, minimal, and mean of at least seven independent experiments,
represented as dots (5 µg/mL) and squares (50 µg/mL), normalized to the number of tertiary veins obtained after exposure to phosphate buffer saline (PBS) and to the
normalized number obtained in the corresponding CAM area at 0 hrs incubation in the same embryo. Dotted line at 100% normalized newly formed vessels refers to the
control sample – number of tertiary veins obtained after exposure to PBS and to the normalized number obtained in the corresponding CAM area at 0 hrs incubation. ***p-
value 0.0003, **p-value 0.0056, *p-value 0.13 comparing to the CAM regions exposed to PBS. p-value was calculated using an unpaired t-test with Welch’s correction.
Abbreviation: PBS, phosphate buffer saline.
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Effect of antiangiogenic-AuNPs
Antiangiogenic-AuNPs with a core diameter of 13±2 nm
were synthesized, coated with OEG for increased stability
and biocompatibility and conjugated with the antiangio-
genic peptide KATWLPPR.21,22,30 Efficient functionaliza-
tion was confirmed by UV-Vis spectroscopy and DLS
(Figure S2A and B).
To understand if the antiangiogenic-AuNPs were able to
counteract the effect on vessel formation induced by K562
derived exosomes, the O-rings were placed on the yolk sack
of chicken embryos, and challenged with four different sus-
pensions: PBS (control); Exosomes from K562 cells (50 µg/
mL); Exosomes from fibroblasts (50 µg/mL); and a mixture
of K562 exosomes (50 µg/mL) and 16.4 nM antiangiogenic-
AuNPs. Since human fibroblasts are a healthy type of cells,
exosomes derived thereof were used as a negative control.
After incubation for 24 and 48 hrs, images of the interior of
each O-ring were acquired (Figure 3A) and the percentage of
newly formed vessels was calculated regarding the number




































Exos Fib Exos K562 + AuNP
K562 exosomes+
antiangiogenic-AuNPsFibroblasts exosomes
Figure 3 Aspect of the CAM areas treated for 24 hrs with phosphate buffer saline (PBS, control), Exosomes from K562 cells (50 µg/mL), Exosomes from fibroblasts (50 µg/
mL), and a mixture of K562 exosomes (50 µg/mL) and 16.4 nM antiangiogenic-AuNPs. (A) Green channel images of the CAM region. (B) Respective segmented image used
to calculate the number of branches. (C) Whiskers plots of the percentage of newly formed vessels obtained 24 and 48 hrs after exposure to Exosomes from K562 cells (50
µg/mL) (Exos K562, black bars with white filling); Exosomes from fibroblasts (50 µg/mL) (Exos Fib, gray bars with light gray filling); a mixture of K562 exosomes (50 µg/mL)
and 16.4 nM antiangiogenic-AuNPs (Exos K562+ AuNP, black bars with dark gray filling). Bars represent the maximum, minimal, and mean of at least six independent
experiments, represented as dots (Exos K562), squares (Exos Fib), or triangles (Exos K562+ AuNP) normalized to the number of tertiary venules obtained in the
corresponding CAM area at 0 hrs incubation in the same embryo and to the number of venules obtained after exposure to PBS. Dotted line at 100% normalized newly
formed vessels refers to the control sample – number of tertiary venules obtained after exposure to PBS and to the normalized number obtained in the corresponding CAM
area at 0 hrs incubation. *1 p-value 0.0113, *2 p-value 0.0212, *3 p-value 0.040 relative to control.
Abbreviations: CAM, chorioallantoic membrane; PBS, phosphate buffer saline.
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At 24 hrs, exosomes derived from fibroblasts had no effect
in angiogenesis as expected (Figure 3C). However, as shown
above, the exosomes derived from K562 cells were able to
induce clear increase to the number of newly formed vessels.
Once these exosomes are administered together with the anti-
angiogenic-AuNPs, the angiogenic effect of exosomes could
be completely blocked (Figure 3C), with a percentage of
newly formed vessels similar to that of the negative control.
Previous studies report a direct correlation between
VEGFR and VEGF mRNA levels and respective protein
levels, leading to the resultant vein phenotypic features.26,31,32
We have previously demonstrated that antiangiogenic-AuNPs
were capable to block the connection between VEGFR-1 and
NRP-1, resulting in decreased expression of several genes,
such as VEGF-A, HIF-1alpha, or c-MYC.22,26 The character-
ization of phenotypic alteration, ie, decrease/increase of num-
ber of emerging veins directly correlates to the modulation of
the respective pathway. To get insights into the mechanism of
antiangiogenic-AuNPs blockage of K562 derived exosomes,
the expression of some pivotal genes in the angiogenesis
process (eg, IL8, VEGFR1, and VEGFA) was analyzed.
Three sets of chicken embryos were prepared with the O-
rings were placed equidistantly on the CAM to ensure that
each embryo is infused by only one treatment: PBS; K562
exosomes (50 µg/mL) (Exos K562); and a mixture of K562
exosomes (50 µg/mL) and 16.4 nM antiangiogenic-AuNPs
(Exos K562+ AuNP). After 12 and 24 hrs incubation, the
CAM was excised, and total RNA extracted to assess
mRNA levels (gene expression) using the 2−ΔΔCt method by
normalization with CAMs treated with PBS (Figure 4).
A 12-hr exposure to K562 exosomes resulted in almost
200-fold increase of VEGFR1, while expression of IL8 and
VEGFA remained similar to that of the control (Figure 4).
These data clearly indicate the triggering of the VEGFR1
dependent pathway to induce neo-angiogenesis. After 24
hrs incubation, the mRNA levels were similar to the PBS
treated sample (control) (Figure 4B). These data are in total
agreement with those of the percentage of newly formed
vessels over time (Figure 2), suggesting that K562
exosomes induce angiogenesis within the first hours of
incubation. What is more, data show that the antiangio-
genic-AuNPs block the action of the angiogenic exosomes
by silencing of the VEGFR1 mediated pathways.
Discussion
The pro-angiogenic effect of K562 derived exosomes was
demonstrated in the highly complex vasculature system of
the CAM. Data show that exosomes trigger a time-depen-
dent effect upon the induction of vessel formation. These
findings corroborate in vivo with those previously attained
for K562 exosome pro-angiogenic effects using in vitro
models.11 In fact, K562 exosomes are capable to induce a
two-fold increase to new vessel formation.
The gene expression profiles highlight the involvement of
VEGF-related pathway. The increased expression of VEGF
receptor is in line with observations made by Mineo and co-
workers who reported that neovascularization in HUVEC
mediated by K562 exosomes is dependent on Src, a family
of protein tyrosine kinases involved in cellular signaling.14
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Figure 4 Whiskers plots of IL8, VEGFA , and VEGFR1 mRNA levels after (A) 12 hrs and (B) 24 hrs of CAM exposure to Exosomes from K562 cells (50 µg/mL) (Exos K562,
red bars with blue dots), or a mixture of K562 exosomes (50 µg/mL) and 16.4 nM antiangiogenic-AuNPs (Exos K562+ AuNP, black bars with gray squares). Data were
normalized relatively to GAPDH mRNA levels and subsequent normalization with CAM treated with PBS. With this procedure, PBS (control) equals to 1 for all analyzed
proteins. *p-value 0.014, **p-value 0.004, *1 p-value 0.035, *2 p-value 0.022 relative to the same gene in CAM treated with exosomes alone.
Abbreviations: CAM, chorioallantoic membrane; PBS, phosphate buffer saline.
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in the VEGF signaling pathway, studies on human retinal
microvascular endothelial cells suggested that VEGFR-1
activation also mediates neovascularization through the
Src-PLD1-PKCγ-cPLA2 signaling pathway.33,34 The time
and dose-dependence on HUVEC differentiation mediated
by LAMA84 derived exosomes were also observed by
Taverna et al11. However, contrary to the results obtained
by Taverna et al, who observed an increased expression of
IL8 in HUVEC after exposure to K562 exosomes, the expres-
sion of IL8 in the highly vascularized CAM remained iden-
tical to the control (Figure 4).11 It should be noted that these
studies were performed with distinct approaches: an in vitro
study, where HUVECs are completely exposed to K562
exosomes; whereas in the herein presented CAM assay, exo-
somes must pass through the epithelium to reach the stroma
where the blood vasculature reside together with lymphatic
system.28 Moreover, the endothelial cells environments are
relevant to the proinflammatory response.35
When CAMs were simultaneously exposed to K562
exosomes and antiangiogenic-AuNPs, the percentage of
newly formed vessels was the same as for the untreated
control, suggesting that the K562 exosomes pro-angio-
genic effect was blocked by the peptides grafted onto the
AuNPs, most likely via a VEGF-dependent cascade. In
fact, the antiangiogenic effect of these nanoconjugates
has been shown to tackle this relevant pathway in
HUVEC and CAM assays.22–24,26
The increased expression ofVEGFA, the agonist of VGFR-
1 after 24 hrs exposure to K562 exosomes and antiangiogenic-
AuNP is of note. In fact, it would be expected a decrease of
VEGFA expression with VEGFR1 as observed by Pedrosa
et al22. The increased expression of VEGFR1, IL8 , and
VEGFA after 12 hrs (Figure 4A) can shed some light on this
question, since it suggests a counter-response mediated by the
antiangiogenic-AuNP to the presence of K562 exosomes.
Exosomes derived from CML cells contain microRNAs
involved in angiogenesis modulation, including miR-126 and
miR-92a, both miRNAs with high homology between humans
and chicken (gga-miR-126 with 100% homology with human
miR-126 and gga-miR-92–1 with 93.24% homology with
human miR-92a-1).10,18,36,37 Studies on mice and zebrafish
revealed that miR-126 is involved in the regulation of vascular
integrity and angiogenesis by repressing negative regulators of
the VEGF pathway, including sprout-related protein,
SPRED1, and phosphoinositol-3 kinase regulatory subunit,
PIK3R2/p85-beta.38,39 Treatment of HUVEC with K562 exo-
some-mediated miR92a suggested that this miRNA is
involved in endothelial cells migration and tube formation.18
Our results suggest that CAM exposure to K562 exosomes
activates the VEGF pathway, resulting in an increased expres-
sion of VEGFR1 (Figure 4A). The inhibition of NRP-1
mediated by the nanoconjugate21,22 exacerbates the CAM
response to the angiogenic activation by K562 exosomes,
triggering an increase of angiogenic mediators, including
IL8, VEGFA, and VEGFR1 (Figure 4A). As the K562 exo-
somes effect fades out with time, the effect of the antiangio-
genic-AuNPs became preponderant, thus decreasing the
expression of VEGFR1. One might consider that, when the
number of newly formed vessels were accounted (Figure 3C),
the effect of the antiangiogenic-AuNP had already balanced
initial trigger by the K562, and thus the percentage of newly
formed vessels was similar to that of the control. Regardless of
the underlying mechanisms inherent to gene expression altera-
tions, the phenotypic features prevail and the effect of the
nanoconjugates was proven effective to inhibit the neo-angio-
genesis mediated by CML-derived exosomes.
Conclusion
Herein, we demonstrate the capability of CML-derived
exosomes to trigger neo-angiogenesis in vivo, which has
got severe implications for understanding tumor develop-
ment, providing cues for biomarkers of prognosis and
eventual antiangiogenic therapeutic strategies. What is
more, by using antiangiogenic-AuNP we were capable to
counteract the effect of CML-derived exosomes in creating
new vessels. This approach may provide for an easy to use
tool to assist further studies for the molecular pathways of
exosome transforming effects in cancer, which in turn
might have relevant implication toward the development
of innovative therapy strategies capable to tackle the bone
marrow tumor microenvironment in CML patients.
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Figure S1 Evaluation of exosome isolation. Supernatant of Fibroblasts and K562 cells was collected, filtered in a 0.2μm filter and concentrated in Centrifugal Filter Devices
with 3KW cut-off. An aliquot of the K562 concentrated supernatant was collected and analysed (Concentrated supernatant K562). Total exosome isolation reagent for
culture media (ThermoFisher) was added to each concentrated supernatant and exosomes collected according to the manufacturer’s instructions (Exos Fibroblasts and Exos
K562). For Western-Blot analysis, 40μg of protein from each sample was separated by SDSPAGE, transferred to a PVDF membrane and stained with Ponceau solution (A).
The presence of CD-81 tetraspanin was then analysed with CD-81 antibody (1D6, Novus biologicals Cat# NB100-65805, RRID:AB_962702) (B). The expected weight of












































Wavelength (nm) Diameter (nm)
700 800
Figure S2 Characterisation of the antiangiogenic-AuNPs. (A) UV–Vis spectra of AuNPs (continuous black line) and antiangiogenic-AuNPs (doted grey line). A red shift of
the surface plasmon resonance peak in the UV–Vis spectrum infers successful functionalisation with the peptide. (B) Dynamic light scattering with diameter distribution of
AuNPs (black bars), with an average diameter of 17·5±0·4nm, and antiangiogenic-AuNPs (grey bars), with an average diameter of 32·8±0·4nm.
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